These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 12122102)
1. Development of an improved vaccine for anthrax. Leppla SH; Robbins JB; Schneerson R; Shiloach J J Clin Invest; 2002 Jul; 110(2):141-4. PubMed ID: 12122102 [No Abstract] [Full Text] [Related]
2. Anthrax. From bioweapons backwater to main attraction. Bohannon J Science; 2003 Apr; 300(5618):414-5. PubMed ID: 12702854 [No Abstract] [Full Text] [Related]
3. Progress and novel strategies in vaccine development and treatment of anthrax. Chitlaru T; Altboum Z; Reuveny S; Shafferman A Immunol Rev; 2011 Jan; 239(1):221-36. PubMed ID: 21198675 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody against the poly-gamma-D-glutamic acid capsule of Bacillus anthracis protects mice from enhanced lethal toxin activity due to capsule and anthrax spore challenge. Jang J; Cho M; Lee HR; Cha K; Chun JH; Hong KJ; Park J; Rhie GE Biochim Biophys Acta; 2013 Mar; 1830(3):2804-12. PubMed ID: 23201204 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model. Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653 [TBL] [Abstract][Full Text] [Related]
8. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection. Reed MD; Wilder JA; Mega WM; Hutt JA; Kuehl PJ; Valderas MW; Chew LL; Liang BC; Squires CH PLoS One; 2015; 10(7):e0130952. PubMed ID: 26207820 [TBL] [Abstract][Full Text] [Related]
9. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913 [TBL] [Abstract][Full Text] [Related]
10. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Staats HF; Alam SM; Scearce RM; Kirwan SM; Zhang JX; Gwinn WM; Haynes BF Infect Immun; 2007 Nov; 75(11):5443-52. PubMed ID: 17709410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]